Milestone Pharmaceuticals (MIST) Q2 FY26 earnings call

Milestone Pharmaceuticals reported solid early progress for its Cardamyst launch in Q2 FY26, marked by growing prescriber breadth and significant expansion in commercial coverage post-quarter end. The company is leveraging its PSVT launch experience to advance its Phase 3 AFib-RVR program, aiming for label expansion. Management expects accelerated growth in the second half of the year as coverage improves and patient activation initiatives begin.